StockData
Innate Pharma SA logo

Innate Pharma SA (IPHA) stock

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.03−0.30 (-22.56%)

Close on Nov 18, 2026Market cap $96.53MP/E –Yield –

Innate Pharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -€52.90M. The highest annual figure on record is €33.65M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€52.90M–
FY2024Dec 31, 2024-€7.29M–
FY2023Dec 31, 2023-€32.91M–
FY2022Dec 31, 2022-€19.69M–
FY2021Dec 31, 2021-€59.39M–
FY2020Dec 31, 2020-€52.67M-256.5%
FY2019Dec 31, 2019€33.65M–
FY2018Dec 31, 2018-€33.40M–
FY2017Dec 31, 2017-€51.02M–

More Innate Pharma figures

See a number that looks wrong?